Collaborations

Affimed seeks to leverage its proprietary technologies through
research partnerships in order to derive further value from its
platforms and more fully exploit their potential.

 
 
     
 
 
Platform Collaborations
 
In 2013, Affimed entered into a license and development agreement with Amphivena, based in San Francisco, CA, to develop an undisclosed product candidate for hematologic malignancies in exchange for an interest in Amphivena and certain milestone payments. Amphivena received funding from MPM Capital, Aeris Capital and Affimed. Amphivena and Janssen have entered into an agreement that gives Janssen the option to acquire Amphivena on predetermined terms, and Janssen provides Amphivena with certain upfront and milestone payments.  Meanwhile, Amphivena has successfully reached its first milestone, the generation of multiple candidate TandAbs with a well specified target profile.  As part of its business development strategy, Affimed aims to increase the number of research collaborations in order to derive further value from its platforms and more fully exploit their potential.
 
  Download poster In vitro and in vivo killing of AML using tetravalent bispecific CD33/CD3 TandAbs
 
  Download poster Construction and Characterization of Novel CD33/CD3 Tandem
Diabodies (TandAbs®) for the Treatment of Acute Myeloid Leukemia (AML)
 
  Download poster Development Of A Bispecific Tetravalent CD33/CD3 TandAb For The Treatment of AML
 
Product Collaborations
 
In August 2013, Affimed signed an agreement with the Leukemia and Lymphoma Society (LLS) under which LLS committed to co-fund up to $4.4 million over two years for the phase 2a development of AFM13. In doing so, the LLS recognized the critical need for safer and more durable therapies for HL. The LLS is committed to advancing breakthrough therapies, particularly for patients with unmet medical needs. The LLS is the world’s largest voluntary health agency dedicated to blood cancer; its mission is: cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and improve the quality of life of patients and their families.
 
 
 
 
 



 
  Impressum Disclaimer